LB PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | $-1.71 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | $-0.67 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | – | $-0.45 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-0.61 | – |
Press releases
Announcements Lb Pharmaceuticals filed with the SEC
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LB Pharmaceuticals Appoints Joseph Miller as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
LB Pharmaceuticals Announces $150 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
Other events · EX-99.1 to Form 8-K
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate
Results of operations · EX-99.1 to Form 8-K
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D.,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LB Pharmaceuticals Announces $100.0 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
Other events · EX-99.1 to Form 8-K
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K